Posts

Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients.

/by

Authors: Javier Vázquez-Bourgon, Víctor Ortiz-García de la Foz, Irene Suarez-Pereira, et al
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20 December 2019
—
INTRODUCTION: Increased incidence of obesity and excess weight lead to an increased incidence of non-alcoholic fatty liver disease (NAFLD). Recent evidence indicates a protective effect of cannabis consumption on weight gain and related metabolic alterations in psychosis patie…

Read more

Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.

/by

Authors: Guy Neff, Christopher O’Brien, Rajender Reddy, Nora Bergasa, Arie Regev, et al
The American Journal of Gastroenterology, August 2002
—
Pruritus due to cholestatic liver disease can be particularly difficult to manage and frequently is intractable to a variety of medical therapies. The aim of our study is to evaluate the efficacy of delta-9-tetrahydrocannabinol (delta-9-THC) for intractable cholestatic related…

Read more